Optimizing Small Cell Lung Cancer Treatment: Synergistic Effects of Chemo and Epigenetic Inhibitors

Overview

Lung cancer involves mutations causing uncontrolled cell growth, with small cell lung cancer (SCLC) making up 15% of cases. SCLC is aggressive, progresses rapidly, and resists treatment. Chemotherapy with high doses of carboplatin and etoposide is the primary treatment. This study tested combining chemotherapy with epigenetic inhibitors, entinostat and SP-2577, on H209 SCLC cells. Cell viability was measured using the Alamar Blue assay, and drug interactions were analyzed using Loewe synergy models. Results showed significant synergy, especially between carboplatin and entinostat, reducing the dosage needed to kill 50% of SCLC cells. These findings suggest epigenetic inhibitors enhance chemotherapy, potentially lowering toxicity and improving treatment outcomes for SCLC patients. The combination strategy offers a promising approach to make standard therapy more effective by allowing dose reduction while maintaining or increasing efficacy. This could lead to better survival rates and fewer side effects in SCLC therapy.

Awards (1)

• Selected for CWSF 2026

Competition history

• CWSF 2026 Disease & Illness

Related projects

Closest projects by meaning, across every fair and year in the corpus.